Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POINT Trial for uveitic macular edema
2016-000304-29Phase 3Terminated
- Sponsor
- MUST Coordinating Centre
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of triamcinolone acetonide, ozurdex and dexamethasone in uveitis and macular edema (3 arms), sponsored by MUST Coordinating Centre. Primary endpoint: Percent change in central subfield macular thickness. Started Feb 2016; status: terminated.
02
Drugs
triamcinolone acetonideozurdexdexamethasone
03
Conditions
uveitismacular edema
Beyond the preview
Go deeper on 2016-000304-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000304-29.